Stories Of A Startup | A Limited Series
PreferUS Healthcare and Kerlan-Jobe Orthopaedic Clinic Announce Next Phase of Partnership
In June of 2021, we made an announcement that would inevitably have an impact not only on PreferUS, but also one of our U.S. institutional partners. In an extended interview with PreferUS Founder and CEO, Mike Franz, he explains this exciting step forward for the company and premiere sports medicine providers, Kerlan-Jobe Orthopaedic Clinic.
"Bridging The Gap" | S1.E3
In our third episode, we focus on establishing and cultivating partnerships with several China hospital systems, with the goal of expanding the PreferUS name within the emerging China healthcare market. Additionally, we highlight one of our more rewarding offerings, the U.S. Immersion Program as well as our newest strategic partner based in Jakarta, Sinar Mas Group. We close with details on our fourth and final episode that will serve as a major announcement for where the future of PreferUS is heading as we join forces with our partner, Kerlan-Jobe Orthopedic Clinic.
"Patience and Persistence" | S1.E2
In our second episode, we will show you how an emerging market demand in China led to diversifying our model and welcoming Oklahoma Heart Hospital and Cedars-Sinai Medical Center as our newest institutional investor partners. Additionally, we introduce you to the PreferUS team from both our Shanghai and Kansas City offices. Each member will share their role, unique work experience, and personal outlook on the future of PreferUS. Lastly, we share our thoughts on the importance of utilizing two distinct characteristics that we've found to be essential to our longevity in an evolving market.
"If We Knew Then, What We Know Now..." | S1.E1
In this introductory episode on the history of PreferUS Healthcare, the audience will be given a firsthand look at the early stages of PreferUS as told by Director of Marketing and Training, David Franz. The story of PreferUS is one that has seen its share of obstacles, achievements, and possesses a will to succeed in the ever-evolving healthcare market of China.